Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
MARKET BRIEF - Miniaturizing Healthcare - From Microelectronics to Nanobiosensing
Cecilia Van Cauwenberghe, MS, Technical Insights Senior Research Analyst, Frost & Sullivan, reports that the proliferation of lower cost microfluidics-based genomics tools offering improved capabilities and allowing more access to end-users is expected to drive this technology for pharmaceutical and biomedical research throughout the next 5 years.
XstalBio Issued US Patent for Stabilization of Therapeutic Proteins
XstalBio Ltd a biologic formulation and drug delivery company recently announced the United States Patent and Trademark Office has issued...DYNAMIC LIGHT SCATTERING - Colloidal Gold: The Gold Standard for Drug Delivery?
Stephen Ball explores the importance of particle size in biomedical nanotechnology. Experimental data are presented to illustrate how advanced DLS techniques deliver these measurements for colloidal gold in the nanosized and sub-nanosized ranges.
Strategic Science & Technologies Initiates Phase I Study to Evaluate Topical Sildenafil
Strategic Science & Technologies recently announced the initiation of a Phase I trial of SST-6006, a first-in-class topical sildenafil product...ADVANCED DELIVERY DEVICES - Innovation Without Change: What is it & What Can it Mean for Pharmaceutical Manufacturers?
John A. Merhige, MEM, and Dan Thayer believe a rigorous, risky development and regulatory process forces pharmaceutical manufacturers into a bad compromise between advances in delivery systems and the time, cost, and risk associated with those advances.
Insys Therapeutics Receives FDA Orphan Drug Designation
Insys Therapeutics, Inc. recently announced that the US FDA has granted orphan drug designation (ODD) to its Liposome Entrapped Paclitaxel...GLOBAL DELIVERY MARKET - Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier
Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.
ABUSE-DETERRENT MARKET - What’s in the Pipeline? Abuse-Deterrent Products
Tugrul Kararli, PhD, MBA, Kurt Sedo, and Josef Bossart, PhD, decided it would be interesting to interrogate the PharmaCircle database and see what successes have been achieved with respect to abuse-deterrent formulations in terms of approved and pipeline products.
DNA VACCINES MARKET - DNA Vaccines: Strategic Markets & Emerging Technologies
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Acorda Therapeutics to Acquire Civitas Therapeutics
Acorda Therapeutics, Inc. recently announced it entered into an agreement to acquire Civitas Therapeutics, a privately held biopharmaceutical company, for...
